EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...

Eylea sales were under pressure in 2023 due to competition from Roche’s Vabysmo. Nevertheless, REGN should benefit from Dupixent’s continued label expansions and solid demand. The approval of ...

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

HAWK and HARRIER also compared brolucizumab and Eylea directly ... The wild card in the wet AMD market is off-label use of Roche’s VEGF inhibitor Avastin (bevacizumab), which continues to ...

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...